Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 93129-94-3 Chemical Structure| 93129-94-3

Structure of Tacalcitol monohydrate
CAS No.: 93129-94-3

Chemical Structure| 93129-94-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tacalcitol promotes normal bone development by regulating calcium.

Synonyms: 1,24(R)-Dihydroxyvitamin D3 monohydrate; 1,24-dihydroxy Vitamin D3 (hydrate); TV 02

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Tacalcitol monohydrate

CAS No. :93129-94-3
Formula : C27H46O4
M.W : 434.65
SMILES Code : CC([C@@H](CC[C@H]([C@@H](CC[C@]1/2[H])[C@@]1(C)CCCC2=C/C=C3C[C@@H](C[C@H](C/3=C)O)O)C)O)C.[H]O[H]
Synonyms :
1,24(R)-Dihydroxyvitamin D3 monohydrate; 1,24-dihydroxy Vitamin D3 (hydrate); TV 02
MDL No. :MFCD13184757

Safety of Tacalcitol monohydrate

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H300
Precautionary Statements:P264-P270-P301+P310+P330-P405-P501
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 cells 100 nM 120 hours To evaluate the antiproliferative effect of Tacalcitol on MDA-MB-231 cells, results showed that Tacalcitol combined with anastrozole significantly inhibited cell proliferation. Int J Mol Sci. 2021 Mar 9;22(5):2781
SKBR-3 cells 100 nM 120 hours To evaluate the antiproliferative effect of Tacalcitol on SKBR-3 cells, results showed that Tacalcitol combined with anastrozole significantly inhibited cell proliferation. Int J Mol Sci. 2021 Mar 9;22(5):2781
T47D cells 10 nM 120 hours To evaluate the antiproliferative effect of Tacalcitol on T47D cells, results showed that Tacalcitol combined with anastrozole significantly inhibited cell proliferation. Int J Mol Sci. 2021 Mar 9;22(5):2781
MCF-7 cells 100 nM 120 hours To evaluate the antiproliferative effect of Tacalcitol on MCF-7 cells, results showed that Tacalcitol combined with anastrozole significantly inhibited cell proliferation. Int J Mol Sci. 2021 Mar 9;22(5):2781
HL-60 cells 8 nM 120 hours To evaluate the antiproliferative effect of Tacalcitol on HL-60 cells, results showed significant antiproliferative activity. Cancers (Basel). 2022 Jan 13;14(2):387
Thp-1 cells 6 nM 120 hours To evaluate the antiproliferative effect of Tacalcitol on Thp-1 cells, results showed significant antiproliferative activity. Cancers (Basel). 2022 Jan 13;14(2):387
MV-4-11 cells 3 nM 120 hours To evaluate the antiproliferative effect of Tacalcitol on MV-4-11 cells, results showed significant antiproliferative activity. Cancers (Basel). 2022 Jan 13;14(2):387
MC38/0 cells 100 nM 120 hours To evaluate the antiproliferative effect of Tacalcitol (PRI-2191) in combination with 5-FU on MC38/0 cells. Results showed that PRI-2191 significantly enhanced the antiproliferative effect of 5-FU on MC38/0 cells. BMC Cancer. 2013 Jun 18;13:294
HT-29 cells 100 nM 120 hours To evaluate the antiproliferative effect of Tacalcitol (PRI-2191) in combination with 5-FU on HT-29 cells. Results showed that PRI-2191 significantly enhanced the antiproliferative effect of 5-FU on HT-29 cells. BMC Cancer. 2013 Jun 18;13:294
MV-4-11 10 nM 48-120 hours Increased proportion of cells in G1/G0 phase, decreased proportion in S phase Int J Mol Sci. 2022 Apr 30;23(9):5019
67NR cells 100 nM 72 hours To evaluate the effect of Tacalcitol and its analogs on the proliferation of 67NR cells. The results showed that Tacalcitol and its analogs significantly inhibited the proliferation of 67NR cells. Int J Oncol. 2018 Jan;52(1):103-126
4T1 cells 100 nM 72 hours To evaluate the effect of Tacalcitol and its analogs on the proliferation of 4T1 cells. The results showed that Tacalcitol and its analogs did not significantly affect the proliferation of 4T1 cells. Int J Oncol. 2018 Jan;52(1):103-126
HL-60 10 nM 72 hours Increased proportion of cells in G1/G0 phase, decreased proportion in S phase Int J Mol Sci. 2022 Apr 30;23(9):5019
MCF-7 cells 1000, 100, 10, 1 nM 72 hours To evaluate the antiproliferative activity of Tacalcitol (PRI-2191) against MCF-7 breast cancer cells. Results showed that Tacalcitol significantly inhibited cell proliferation at 100 nM concentration. Cancers (Basel). 2013 Oct 31;5(4):1355-78
Thp-1 10 nM 96 hours Increased proportion of cells in G1/G0 phase, decreased proportion in S phase Int J Mol Sci. 2022 Apr 30;23(9):5019

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 female mice MC38 mouse colon cancer model Subcutaneous injection 1 μg/kg/day Three times a week, until the end of the experiment To evaluate the antitumor effect of Tacalcitol (PRI-2191) in combination with 5-FU on the MC38 mouse colon cancer model. Results showed that the combined treatment significantly inhibited tumor growth and prolonged the survival time of mice. BMC Cancer. 2013 Jun 18;13:294
BALB/c mice 4T1 mammary tumor model Subcutaneous injection 1.0 µg/kg Three times a week, starting from day 7 after tumor inoculation To assess the effect of Tacalcitol on Th17 cells in the 4T1 tumor model in young and aged OVX mice. Results showed that Tacalcitol increased Th17 cell gene expression and IL-17A secretion in young mice but decreased these effects in aged OVX mice. Aging Dis. 2020 Mar 9;11(2):241-253
SCID mice MCF-7 breast cancer model Subcutaneous injection 1.0 μg/kg Three times a week for 46 days To evaluate the antitumor effect of Tacalcitol in vivo on MCF-7 tumor growth, results showed that Tacalcitol significantly inhibited tumor growth. Int J Mol Sci. 2021 Mar 9;22(5):2781
NU/J mice Subcutaneous human breast MCF-7 tumor model Subcutaneous injection 1.0 μg/kg/day Three times a week, up to day 67 of the experiment To evaluate the antitumor activity of Tacalcitol (PRI-2191) in the MCF-7 breast cancer model. Results showed that PRI-2191 significantly inhibited tumor growth on days 60 and 62 of the experiment. Cancers (Basel). 2013 Oct 31;5(4):1355-78
BALB/c female mice 4T1 mouse mammary gland cancer model Subcutaneous injection PRI-2191, 1.0 µg/kg Thrice a week, starting from day 7 after tumor inoculation To evaluate the effect of Tacalcitol analog PRI-2191 on tumor growth and metastasis in the 4T1 mouse mammary gland cancer model. The results showed that PRI-2191 did not influence the growth of primary tumors but significantly increased lung metastasis. Int J Oncol. 2018 Jan;52(1):103-126

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.30mL

0.46mL

0.23mL

11.50mL

2.30mL

1.15mL

23.01mL

4.60mL

2.30mL

References

 

Historical Records

Categories